0001321732FALSE00013217322024-03-172024-03-17

__________________________________________________________________________________________________________________________

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________________________________________________________________________________

FORM 8-K 
_______________________________________________________________________________________________________________________________

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

August 13, 2024
Date of Report (Date of earliest event reported) 
_______________________________________________________________________________________________________________________________

Penumbra, Inc.
(Exact name of registrant as specified in its charter)
_______________________________________________________________________________________________________________________________
Delaware001-3755705-0605598
(State or other jurisdiction of incorporation or organization)(Commission File No.)(I.R.S. employer identification number)
One Penumbra Place
Alameda, CA 94502
(Address of principal executive offices, including zip code)
 
(510) 748-3200
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, Par value $0.001 per sharePENThe New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

_______________________________________________________________________________________________________________________________


Item 8.01.
Other Events.
On August 13, 2024, Penumbra, Inc. issued a press release announcing its entry into an accelerated share repurchase agreement. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
 Press release of Penumbra, Inc. dated August 13, 2024.
104Cover Page Interactive Data File (formatted as Inline Extensible Business Reporting Language).




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 Penumbra, Inc.
   
Date: August 13, 2024By:/s/ Maggie Yuen
  Maggie Yuen
  Chief Financial Officer



Exhibit 99.1

image_0.jpg


    



Penumbra, Inc. Announces $200 Million Share Repurchase Authorization
To Include $100 Million Accelerated Share Repurchase

ALAMEDA, Calif., Aug. 13, 2024 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of up to $200 million, allowing Penumbra to repurchase its common stock from time to time at such prices as it deems appropriate through open market purchases, block transactions, privately negotiated transactions, including accelerated share repurchase transactions, or otherwise. The repurchase authorization expires on July 31, 2025.

Under this authorization, Penumbra entered into an accelerated share repurchase agreement (“ASR”) with JPMorgan Chase Bank, National Association (the “Dealer”) on August 12, 2024 to repurchase $100 million of Penumbra’s common stock.

Under the ASR, Penumbra will make an initial payment of $100 million to the Dealer and will receive an initial delivery of approximately 474,000 shares of Penumbra’s common stock on August 13, 2024. The final number of shares to be repurchased will be based on the average of the daily volume-weighted average prices of Penumbra’s common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms of the ASR. The final settlement of the ASR is expected to be completed in the third quarter of 2024. Penumbra is funding the share repurchase under the ASR with cash on hand.

Cautionary Statement Concerning Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions. These statements are neither promises nor guarantees but involve a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Forward-looking statements in this communication include, but are not limited to, statements about Penumbra’s share repurchase program, the transactions under the ASR, and the expected completion date of the ASR. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate Penumbra’s current customer base, expand Penumbra’s user base and increase the frequency of use of Penumbra’s products by its customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of Penumbra’s inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain its culture as Penumbra grows; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments Penumbra may make; and other factors and other risks, including those that Penumbra has described in its filings with the Securities and Exchange Commission, including but not limited to its Annual Reports on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. There may be additional risks of which Penumbra is not presently aware or that it currently believe are immaterial which could have an adverse impact on its business. Any forward-looking statements are based on Penumbra’s current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. Penumbra makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Penumbra undertakes no obligation to update the information contained in this press release except as required by law.

About Penumbra
Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Investor Relations
Penumbra, Inc.
investors@penumbrainc.com

Source: Penumbra, Inc.


v3.24.2.u1
Cover
Mar. 17, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 13, 2024
Entity Registrant Name Penumbra, Inc.
Entity Central Index Key 0001321732
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-37557
Entity Tax Identification Number 05-0605598
Entity Address, Address Line One One Penumbra Place
Entity Address, City or Town Alameda
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94502
City Area Code 510
Local Phone Number 748-3200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par value $0.001 per share
Trading Symbol PEN
Security Exchange Name NYSE
Entity Emerging Growth Company false
Penumbra (NYSE:PEN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024 Haga Click aquí para más Gráficas Penumbra.
Penumbra (NYSE:PEN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Penumbra.